Meta Biomed Co (059210) Fair Value & Analysis
Healthcare · KR · Market cap 104B KRW
Fair value as of: Jul 22, 2026
From 14 valuation models · updated 19 days ago
Share price +5.6% over the past month.
Below-average quality, screening 104% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (4,898 KRW). The market is more pessimistic than our downside scenario.
- A fairly wide model range (4,898 KRW to 9,367 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,964 KRW – 6,383 KRW · fair‑value band 4,898 KRW – 9,367 KRW · the 4,120 KRW price screens below the 8,394 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Meta Biomed Co (059210) currently trades at 4,120 KRW, while our model-based Fair Value estimate is 8,394 KRW, implying the stock looks roughly 103.7% undervalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Meta Biomed Co generated revenue of 66.9B KRW at a net margin of 10.9%. Revenue grew 40.4% year over year. Net debt stands at 24.1B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 4,898 KRW (bear case) to 9,367 KRW (bull case); at 4,120 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at 104%, 059210 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (10,290 KRW) versus Asset-Based (3,545 KRW). Highest evidence: Residual Income (76).
Notify me when 059210 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials.
Full company description
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products, as well as ultrasonic imaging diagnosis devices. The company was formerly known as Metadental Co., Ltd. and changed its name to Meta Biomed Co., Ltd. in 2001. Meta Biomed Co., Ltd. was founded in 1990 and is headquartered in Cheongju, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Meta Biomed Co reported revenue of 103B KRW in FY2025 versus 58.8B KRW in FY2021, a compound +15.0%/yr. Reported net income was 11.0B KRW in FY2025, compounding +3.6%/yr from FY2021.
Watch 059210: get an alert when its fair value changes →
Peer Group
Health Care · 2227 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 50,900 KRW | 49,984 KRW | -2% |
| i-SENS, Inc 099190 | 15,270 KRW | 8,168 KRW | -47% |
| Value Added Technology Co 043150 | 16,800 KRW | 60,242 KRW | +259% |
| Mediana Co 041920 | 8,940 KRW | 6,289 KRW | -30% |
| Sewoon Medical Co 100700 | 2,245 KRW | 6,054 KRW | +170% |
| MEDIC MEDIC | 0.2100 PHP | 0.1400 PHP | -33% |
| MEKICS CO., Ltd 058110 | 1,780 KRW | 1,584 KRW | -11% |
| CU Medical Systems, Inc 115480 | 1,753 KRW | 1,134 KRW | -35% |
| PeopleBio, Inc 304840 | 857.00 KRW | 905.70 KRW | +6% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
Compare Meta Biomed Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Meta Biomed Co (059210) overvalued or undervalued?
What is the fair value of 059210?
What is the quality score of 059210?
What is the revenue of Meta Biomed Co (059210)?
What is the net profit margin of 059210?
Does Meta Biomed Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Meta Biomed Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.